Power3 Medical Products Files to Regain NASDAQ Listing
Posted on: Monday, 27 February 2006, 12:01 CST
Power3 Medical Products, Inc. (PWRM.PK), a leader in the development of blood serum-based diagnostic tests for early-detection of cancer and neurodegenerative diseases, said today that it has filed all appropriate forms to regain its NASDAQ(R) listing.
Citing "growing interest in our scientific efforts and our work to successfully commercialize our tests," Steven B. Rash, the company's chairman and CEO, said Power 3 is "eager to return to the NASDAQ, where our investors will have greater liquidity, new investors can more easily learn about us, and where our progress can be more readily tracked by institutions."
He said a series of articles in the Houston Chronicle "helped spur strong interest in Power3" earlier in February.
"On February 5th - Super Bowl Sunday - the Chronicle ran four articles and more than 3,000 words covering the study and use of proteomics in general and Power3 Medical in particular," he said.
"It was an awakening for many," he said. "Power3's shares soared by more than 330% over the next six days as some 7 million shares traded, including one day with 2.4 million. Quite a ride!"
Mr. Rash said interest in Power3 has "continued to grow, and we are doing everything we can to facilitate a speedy return to the NASDAQ."
About Power3 Medical Products, Inc.
Power3 Medical Products, Inc. (PWRM.PK) is a leading proteomics company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease, and its identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 operates a state-of-the-art proteomics laboratory in The Woodlands (Houston), Texas.
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.
Source: Business Wire
Related Articles
- Siemens Medical Solutions Diagnostics Introduces MicroScan WalkAway Plus Microbiology Systems
- ICx Technologies and Siemens Medical Solutions Diagnostics Enter In Vitro Diagnostics Development and License Option Agreement
- Siemens Medical Solutions Diagnostics Announces Agreement With Amerinet to Provide Integrated Automation, Chemistry and Immunoassay Solutions
- Siemens Medical Solutions Diagnostics Announces Enhanced Liver Fibrosis Test for Europe
- Hospitals, Healthcare Providers to Save With Premier Auditory Screening and Diagnostic Products Agreements
- IsoRay Medical, Inc. Begins Production Testing of Its Proprietary Cesium-131 Isotope Through Agreement With Idaho National Laboratory
- CHF Solutions Named One of 50 Companies to Watch By Medical Device & Diagnostic Industry Magazine
- Diagnostic Products Corporation Releases NT-proBNP Assay Outside the US
- Lifeline Biotechnologies Successfully Completes Testing of MastaScope Diagnostic Product in China
- 2005 Over The Counter Diagnostic Products Growing at 15% Per Year Over Next Five Years
 |
 |
User Comments (0)
RSS Feeds